PDCD1 and non-small cell lung carcinoma: Recent clinical trials have indicated that the inhibition of this pathway with anti-PD-1/PD-L1 antibodies exerts a promising antitumor effect against several human malignancies, including NSCLC, melanoma, and renal cell cancer [8–14].